- Clearmind Medicine (CMND, Financial) has initiated all clinical trial sites for its Phase I/IIa trial on Alcohol Use Disorder (AUD).
- FDA and IRB approvals secured, patient enrollment set to begin at Yale, Johns Hopkins, and IMCA Center.
- CMND-100 drug candidate successfully manufactured and imported for trial testing.
Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, has successfully initiated all the planned sites for its Phase I/IIa clinical trial in Alcohol Use Disorder (AUD). This trial will take place at prestigious institutions, including the Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine, and the IMCA Center in Israel.
The company has completed all the necessary preparations to start the clinical trial. This includes securing FDA approval for the Investigational New Drug (IND) application, obtaining Institutional Review Board (IRB) approvals from each site, and implementing an Electronic Data Capture (EDC) system to facilitate the trial.
Clearmind Medicine's trial will evaluate CMND-100, its drug candidate aimed at treating alcoholism. The drug has been successfully manufactured and imported into the United States, paving the way for the enrollment of patients in the study.
The initiation of this clinical trial marks a critical development milestone for Clearmind Medicine in its mission to address the unmet medical needs in treating alcohol use disorder. As the company collaborates with renowned research institutions, it seeks to test the safety and preliminary efficacy of CMND-100, which could potentially transform the treatment landscape for alcoholism.
